secwatch.observer — SEC 8-K summary
======================================

Issuer:     COGNITION THERAPEUTICS INC (CGTX)
CIK:        0001455365
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001104659-23-088580
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cognition Therapeutics Q2 net loss $4.7M; positive SEQUEL topline for CT1812
----------------------------------------------------------------------------

- Net loss of $4.7M ($0.16/sh) vs $5.8M ($0.25/sh) in Q2 2022; R&D expense $8.5M.
- Cash and equivalents $37.2M; NIA grants remaining $81.8M; cash runway through Q3 2024.
- Positive topline results from Phase 2 SEQUEL qEEG study; full data expected Q4 2023.
- 540-patient Phase 2 START trial (early Alzheimer's) recruiting; MAGNIFY dry AMD dosing started.
- Published SNAP study confirming sigma-2 receptor target engagement of CT1812.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1455365/000110465923088580/0001104659-23-088580-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1455365/000110465923088580/tm2322819d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-088580

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer